CN Patent

CN119619321B — 多囊脂质体组合物的分析方法

Assigned to Hunan Kelun Pharmaceutical Research Co Ltd · Expires 2025-12-26 · 0y expired

What this patent protects

本发明公开了一种多囊脂质体组合物的分析方法，属于药物分析技术领域。本发明的分析方法为采用C8色谱柱，缓冲液水溶液和有机相为流动相，梯度洗脱，分析分离多囊脂质体组合物组成成分、水解产物，并定量计算其组成成分、水解产物含量，本发明有利于更好地监控多囊脂质体组合物产品的质量，为多囊脂质体组合物的开发提供有力保障。

USPTO Abstract

本发明公开了一种多囊脂质体组合物的分析方法，属于药物分析技术领域。本发明的分析方法为采用C8色谱柱，缓冲液水溶液和有机相为流动相，梯度洗脱，分析分离多囊脂质体组合物组成成分、水解产物，并定量计算其组成成分、水解产物含量，本发明有利于更好地监控多囊脂质体组合物产品的质量，为多囊脂质体组合物的开发提供有力保障。

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (BUPIVACAINE) · Innocoll

Patent Metadata

Patent number: CN119619321B
Jurisdiction: CN
Classification: —
Expires: 2025-12-26
Drug substance claim: No
Drug product claim: No
Assignee: Hunan Kelun Pharmaceutical Research Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.